Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2022-08-19 Investor Presentation
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Investor Presentation Classification · 98% confidence The document is explicitly titled 'Second Quarter 2022 Presentation' and contains a 'Table of Contents' listing 'Highlights Q2 2022', 'Operational Update Q2 2022', and 'Key financials Q2 2022 & Newsflow'. It includes detailed clinical trial updates (INITIUM, NIPU, FOCUS, DOVACC, LUNGVAC, TENDU) and a table of key financial figures comparing Q2-22 results against previous periods. This structure is characteristic of an Investor Presentation (IP) or a management/operational update presentation, rather than a formal regulatory filing like a 10-K or a standalone Earnings Release (ER). Since it is a detailed presentation format covering operations, financials, and pipeline progress, 'Investor Presentation' (IP) is the most appropriate classification.
2022-08-19 English
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter of 2022 (Q2 2022) for Ultimovacs ASA. It contains detailed operational highlights, clinical trial updates, a CEO statement, and actual financial statements (unaudited) including income statements and cash flow data. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2022
2022-08-19 English
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Earnings Release Classification · 100% confidence The document is titled "Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update". It explicitly details financial figures for Q2-22 (operating expenses, loss, cash flow) and provides a comprehensive update on clinical trial progress, scientific publications, and management commentary. This structure—covering financial performance for a specific interim period (Q2) along with operational updates—is characteristic of an Interim/Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not the full annual report (10-K). Since it contains the actual financial results for the period, it is classified as IR, not RPA. Q2 2022
2022-08-19 English
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
Regulatory Filings Classification · 95% confidence The document is a press release dated August 18, 2022, announcing an update regarding a clinical trial (TENDU Phase I) for a prostate cancer vaccine. Specifically, it states that the company is expanding the high dose cohort size after a safety review showed no concerns. This type of announcement, detailing progress, safety updates, or minor operational changes in clinical development, is typically classified as a general regulatory announcement or news release, rather than a formal financial report (like 10-K or IR) or a specific investor presentation (IP). Since it is a formal announcement published via stock exchange channels (implied by the closing statement regarding EU Market Abuse Regulation and Norwegian Securities Trading Act), and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2022-08-18 English
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1174 characters) from Ultimovacs ASA inviting stakeholders to a webcast presentation for their 'second quarter 2022 results' scheduled for August 19, 2022. It explicitly states that the 'report and presentation will be available on the company website from 08:00 CET the same day.' This structure—an invitation to view results/reports that are published elsewhere—fits the definition of a Report Publication Announcement (RPA). It is not the full Interim Report (IR) or Earnings Release (ER) itself, but the notice about their publication and associated presentation event.
2022-08-12 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document text explicitly uses the template title "KRT-1500 Template for notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them." It details a transaction (Acquisition of 2,000 shares) by a CEO (Carlos David Freitas De Sousa) and reports this information to the Norwegian Financial Supervisory Authority (FINANSTILSYNET). This type of filing specifically reports personal share transactions by company directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS).
2022-06-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.